Dyne Therapeutics Inc DYN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 03/28/24 EDT
28.70quote price arrow up+0.31 (+1.09%)
Volume
68,205
Close
28.39quote price arrow down-0.11 (-0.39%)
Volume
1,253,565
52 week range
6.40 - 30.27
Loading...
  • Open28.51
  • Day High29.00
  • Day Low27.27
  • Prev Close28.50
  • 52 Week High30.27
  • 52 Week High Date03/01/24
  • 52 Week Low6.40
  • 52 Week Low Date10/30/23

Key Stats

  • Market Cap2.327B
  • Shares Out81.96M
  • 10 Day Average Volume1.85M
  • Dividend-
  • Dividend Yield-
  • Beta0.95
  • YTD % Change113.46

KEY STATS

  • Open28.51
  • Day High29.00
  • Day Low27.27
  • Prev Close28.50
  • 52 Week High30.27
  • 52 Week High Date03/01/24
  • 52 Week Low6.40
  • 52 Week Low Date10/30/23
  • Market Cap2.327B
  • Shares Out81.96M
  • 10 Day Average Volume1.85M
  • Dividend-
  • Dividend Yield-
  • Beta0.95
  • YTD % Change113.46

RATIOS/PROFITABILITY

  • EPS (TTM)-3.94
  • P/E (TTM)-7.21
  • Fwd P/E (NTM)-8.48
  • EBITDA (TTM)-240.487M
  • ROE (TTM)-137.31%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/09/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Dyne Therapeutics Inc

 

Profile

MORE
Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it...
Jason Rhodes
Independent Chairman of the Board
John Cox
President, Chief Executive Officer, Director
Susanna High
Chief Operating Officer
Address
1560 Trapelo Road
Waltham, MA
02451
United States

Top Peers

SYMBOLLASTCHG%CHG
KROS
Keros Therapeutics Inc
66.20+1.54+2.38%
CLDX
Celldex Therapeutics Inc
41.97+0.18+0.43%
RNA
Avidity Biosciences Inc
25.52+0.85+3.45%
RCKT
Rocket Pharmaceuticals Inc
26.94-0.31-1.14%
JANX
Janux Therapeutics Inc
37.65-0.27-0.71%